EGFR and non-small cell lung carcinoma: By inhibiting the binding of ATP to EGFR, the drug restrains auto-phosphorylation and the activation of downstream signaling pathway further, leading to the inhibition of cell proliferation and inducing apoptosis in NSCLC.